Conmed (CNMD) EBIT (2010 - 2026)

Conmed has reported EBIT for 17 years, with the latest figure at $25.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 59.26% year-over-year to $25.4 million; the trailing twelve-month figure through Mar 2026 stood at $112.1 million (down 38.17% YoY), and the FY2025 full-year result was $102.6 million, down 48.77% from the prior year.
• EBIT for Q1 2026 stood at $25.4 million, down from $36.6 million in the prior quarter.
• The five-year high for EBIT was $65.7 million in Q3 2024, with the low at -$1.1 million in Q4 2022.
• Historically, EBIT has averaged $30.5 million across 5 years, with a median of $27.4 million in 2023.
• Annual changes were most pronounced in 2022 — EBIT plunged 102.94% — and 2023, when it surged 4683.29%.
• Conmed's EBIT stood at -$1.1 million in 2022, then surged by 4683.29% to $50.2 million in 2023, then increased by 4.61% to $52.5 million in 2024, then plunged by 30.24% to $36.6 million in 2025, then plunged by 30.61% to $25.4 million in 2026.
• The last three EBIT figures came in at $25.4 million (Q1 2026), $36.6 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.